.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,790,755

« Back to Dashboard
Patent 7,790,755 protects DEXILANT and is included in one NDA. There have been two Paragraph IV challenges on Dexilant. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,790,755

Title:Controlled release preparation
Abstract:A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
Inventor(s): Akiyama; Yohko (Osaka, JP), Kurasawa; Takashi (Osaka, JP), Bando; Hiroto (Osaka, JP), Nagahara; Naoki (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/531,069
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 84th percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
DEXILANT
dexlansoprazole
CAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXNo7,790,755*PED► subscribeY
Takeda Pharms Usa
DEXILANT
dexlansoprazole
CAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009RXYes7,790,755*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,790,755

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-301876Oct 16, 2002
Japan2003-066336Mar 12, 2003
PCT Information
PCT FiledOctober 15, 2003PCT Application Number:PCT/JP03/13155
PCT Publication Date:April 29, 2004PCT Publication Number: WO2004/035020

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc